LADENBURG THALM/SH SH Initiates Coverage on Elicio Therapeutics (NASDAQ:ELTX)

Research analysts at LADENBURG THALM/SH SH assumed coverage on shares of Elicio Therapeutics (NASDAQ:ELTX) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. LADENBURG THALM/SH SH’s price target points to a potential upside of 58.73% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Elicio Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. HC Wainwright increased their target price on shares of Elicio Therapeutics from $13.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, Rodman & Renshaw upgraded shares of Elicio Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Elicio Therapeutics Trading Up 7.0%

Shares of Elicio Therapeutics stock opened at $12.60 on Wednesday. The stock has a market capitalization of $231.84 million, a P/E ratio of -4.81 and a beta of 1.11. The company has a quick ratio of 2.38, a current ratio of 2.38 and a debt-to-equity ratio of 5.75. The company has a 50-day simple moving average of $10.66 and a 200 day simple moving average of $9.48. Elicio Therapeutics has a 12-month low of $4.70 and a 12-month high of $14.93.

Elicio Therapeutics (NASDAQ:ELTX) last announced its earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Research analysts expect that Elicio Therapeutics will post -3.89 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elicio Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Elicio Therapeutics by 4.2% in the 3rd quarter. Vanguard Group Inc. now owns 473,859 shares of the company’s stock valued at $5,184,000 after acquiring an additional 19,240 shares in the last quarter. Geode Capital Management LLC increased its position in Elicio Therapeutics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 132,518 shares of the company’s stock valued at $1,055,000 after acquiring an additional 2,832 shares in the last quarter. Susquehanna International Group LLP increased its position in Elicio Therapeutics by 606.1% in the 3rd quarter. Susquehanna International Group LLP now owns 120,207 shares of the company’s stock valued at $1,315,000 after acquiring an additional 103,184 shares in the last quarter. Marshall Wace LLP increased its position in Elicio Therapeutics by 35.4% in the 4th quarter. Marshall Wace LLP now owns 117,200 shares of the company’s stock valued at $933,000 after acquiring an additional 30,667 shares in the last quarter. Finally, 683 Capital Management LLC acquired a new stake in Elicio Therapeutics in the 4th quarter valued at about $449,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.